Investment Opportunities in Our Ophthalmology Patents
At Advanced Euclidean Solutions, we offer a strategic overview of our pioneering intellectual property (IP) in ophthalmology. Our portfolio showcases significant innovations with the potential to transform eye care and patient outcomes worldwide.
We invite forward-thinking investors to explore these healthcare breakthroughs and join us in advancing the future of vision care.
Claims Enhanced by AI
All of our patent claims were allowed and issued, including a virtual “in the cloud” device that accumulates data, stores it, and uses our methodology to improve itself.
Next-Generation Intraocular
Lens CalculationsOur first patent involved AI based optimization of ANY formula (including our own) for calculating intraocular lens power in cataract surgery, which is performed approximately 4 million times annually in the US and 20 million times annually worldwide.
Refractive Surgery
Outcome OptimizationOur second patent will apply the same AES artificial intelligence methodologies for improving outcomes for all corneal refractive surgery procedures such as LASIK, PRK, SMILE, etc., which are performed approximately 1 million times annually in the US and approaching 10 million times annually worldwide.
Age-Related
Macular DegenerationAnother patent in the early stages that involves optimizing medical decision-making for intraocular injections for macular degeneration and related diseases which are performed approximately 8 million times annually in the US and 20 million times annually worldwide.
Connect With Us
We're eager to discuss the future of ophthalmology and our role in shaping it. Whether you're a potential investor, a healthcare professional, or simply curious about our advancements, we invite you to get in touch.